Trader consensus assigns a 77.5% probability to no new COVID variant of concern before 2027 because circulating SARS-CoV-2 lineages remain within established Omicron descendants such as XFG, NB.1.8.1, and PQ.16.1.1, which show modest immune escape and transmissibility gains but no rise in disease severity. WHO and CDC risk evaluations classify these as variants under monitoring rather than variants of concern, with BA.3.2 displaying greater divergence yet limited competitive fitness. Recent FDA advisory approval of XFG-targeted vaccines for the 2026–2027 season and sustained low hospitalization rates reflect high population immunity and effective surveillance. A formal reclassification would require documented increases in virulence or major public health impact that have not materialized in 2026 data.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado¿Nueva variante COVID de preocupación antes de 2027?
Sí
$245,847 Vol.
$245,847 Vol.
Sí
$245,847 Vol.
$245,847 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercado abierto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus assigns a 77.5% probability to no new COVID variant of concern before 2027 because circulating SARS-CoV-2 lineages remain within established Omicron descendants such as XFG, NB.1.8.1, and PQ.16.1.1, which show modest immune escape and transmissibility gains but no rise in disease severity. WHO and CDC risk evaluations classify these as variants under monitoring rather than variants of concern, with BA.3.2 displaying greater divergence yet limited competitive fitness. Recent FDA advisory approval of XFG-targeted vaccines for the 2026–2027 season and sustained low hospitalization rates reflect high population immunity and effective surveillance. A formal reclassification would require documented increases in virulence or major public health impact that have not materialized in 2026 data.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado



Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes